Q-omics provides the consensus-scored DEFB119 profile across patient tissues and cancer cell-line models. DEFB119 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, DEFB119 is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, DEFB119 RNA expression shows 6,721 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCS, KIRC, and STAD as cancer lineages where DEFB119 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DEFB119 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DEFB119 survival associations across molecular data types. DEFB119 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DEFB119 RNA expression–survival associations across cancer types. High DEFB119 expression shows unfavorable associations in UCS, KICH, KIRC, COAD, OV and UVM. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for DEFB119 RNA expression.
This table summarizes DEFB119 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DEFB119. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DEFB119 shows lower tumor expression in STAD and higher tumor expression in KIRC. The KIRC box plot shows higher DEFB119 RNA expression in tumor versus normal tissue (log2 FC = +0.029, t-test p = .007).
This table shows molecular features associated with DEFB119 in patient tissues and cancer cell lines. In patient samples, DEFB119 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, DEFB119 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and UPPER_AERODIGESTIVE_TRACT.
